Mindful Awareness in Body-Oriented Therapy (MABT) improved emotion regulation, reduced craving, and promoted abstinence in women with a history of trauma and emotional problems receiving outpatient treatment for substance use disorder.
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.
A recent NIDA-sponsored study found higher rates of NAS among males than among females. A second study found that, among infants whose mothers were treated with buprenorphine while pregnant, NAS was more severe among those whose mothers used other substances.
In this international trial, participants who received the intervention engaged in HIV treatment, achieved viral suppression at higher rates, and died at half the rate of participants in a control group.
Several effective medications are now available for treating opioid use disorder but many patients who could benefit do not receive them. Some patients who receive the medications face challenges to staying in treatment.
A clinical trial found that patients who self-administered cognitive behavioral therapy (CBT) using computerized training modules reduced their drug use as much as patients who received clinician-delivered CBT, and they maintained this advantage through a 6-month follow-up.